14 hours ago
argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.
Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions.
The main ***** et involved is FB102, Forte Biosciences' first-in-class anti-CD122 antibody, which will be added to argenx's immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease.
These studies were a key factor in deciding to proceed from a strategic investment to acquisition by argenx.
Forte Biosciences expects to release Phase II data for FB102 in the second half of this year.
#forte #biosciences
Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions.
The main ***** et involved is FB102, Forte Biosciences' first-in-class anti-CD122 antibody, which will be added to argenx's immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease.
These studies were a key factor in deciding to proceed from a strategic investment to acquisition by argenx.
Forte Biosciences expects to release Phase II data for FB102 in the second half of this year.
#forte #biosciences
6 days ago
Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward while Energy and Utilities lagged due to falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index in the quarter, driven by strong performances in the Industrials and Health Care sectors, while Financials and Consumer Discretionary detracted from the performance. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted Forte Biosciences, Inc. (NASDAQ:FBRX). Forte Biosciences, Inc. (NASDAQ:FBRX), a US-based clinical-stage biopharmaceutical company, detracted from the Fund's performance during the quarter. On July 20, 2026, Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $47.49 per share, reflecting a market capitalization of $972.54 million. Forte Biosciences, Inc. (NASDAQ:FBRX) posted a one-month return of 161.65%, while its shares gained 355.32% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding Forte Biosciences, Inc. (NASDAQ:FBRX) in its Q2 2026 investor update:
"Forte Biosciences, Inc. (NASDAQ:FBRX) is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody with potential application across a range of autoimmune conditions, including celiac disease, vitiligo, and alopecia areata. We view Forte favorably given the differentiated mechanism underlying FB102 and its potential applicability across multiple sizeable indications, supported by encouraging early celiac data and a series of meaningful clinical readouts anticipated through the balance of the year. Shares detracted from performance during the quarter, pressured by an equity raise whose limited initial disclosure was poorly received, as well as by growing investor impatience as anticipated vitiligo data extended beyond the previously communicated timeline. Despite a challenging quarter, we remain constructive ahead of the celiac readout expected later this year and cautiously optimistic on the forthcoming vitiligo results. We believe FB102 retains meaningful strategic value as its clinical profile comes into clearer focus."
#forte #biosciences #small #investor
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted Forte Biosciences, Inc. (NASDAQ:FBRX). Forte Biosciences, Inc. (NASDAQ:FBRX), a US-based clinical-stage biopharmaceutical company, detracted from the Fund's performance during the quarter. On July 20, 2026, Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $47.49 per share, reflecting a market capitalization of $972.54 million. Forte Biosciences, Inc. (NASDAQ:FBRX) posted a one-month return of 161.65%, while its shares gained 355.32% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding Forte Biosciences, Inc. (NASDAQ:FBRX) in its Q2 2026 investor update:
"Forte Biosciences, Inc. (NASDAQ:FBRX) is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody with potential application across a range of autoimmune conditions, including celiac disease, vitiligo, and alopecia areata. We view Forte favorably given the differentiated mechanism underlying FB102 and its potential applicability across multiple sizeable indications, supported by encouraging early celiac data and a series of meaningful clinical readouts anticipated through the balance of the year. Shares detracted from performance during the quarter, pressured by an equity raise whose limited initial disclosure was poorly received, as well as by growing investor impatience as anticipated vitiligo data extended beyond the previously communicated timeline. Despite a challenging quarter, we remain constructive ahead of the celiac readout expected later this year and cautiously optimistic on the forthcoming vitiligo results. We believe FB102 retains meaningful strategic value as its clinical profile comes into clearer focus."
#forte #biosciences #small #investor
12 days ago
Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple.
On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution incorporates about 4,000 of the largest U.S. companies, based on their market capitalization as of the April 30 close.
M. A. Arkhipov/Shutterstock.com
Inclusion in the Russell 3000 Index results in automatic addition to either the Russell 1000 Index or the Russell 2000 Index. It also leads to inclusions across indexes that cover value or growth tilts.
CEO David Happel said this development speaks volumes about what Sagimet has achieved over the years, with people now expecting the company to start its Phase 3 clinical study on denifanstat. He further stated:
On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution incorporates about 4,000 of the largest U.S. companies, based on their market capitalization as of the April 30 close.
M. A. Arkhipov/Shutterstock.com
Inclusion in the Russell 3000 Index results in automatic addition to either the Russell 1000 Index or the Russell 2000 Index. It also leads to inclusions across indexes that cover value or growth tilts.
CEO David Happel said this development speaks volumes about what Sagimet has achieved over the years, with people now expecting the company to start its Phase 3 clinical study on denifanstat. He further stated:
12 days ago
Heartland Advisors, an investment management company, released its second-quarter 2026 investor letter for "Heartland Mid Cap Value Fund". A copy can be downloaded here. Mid-cap stocks sharply rose in the second quarter, driven by perceived AI beneficiaries, particularly in Technology. The Fund returned 9.90% in the quarter, compared to the Russell Midcap® Value Index's 13.40% return. The underperformance was driven by negative stock selection despite Tech being one of the top absolute return contributors. In the challenging environment, the Fund remains focused on its disciplined approach to security selection. In addition, you can check the Fund's top 5 holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, Heartland Mid Cap Value Fund highlighted International Flavors & Fragrances Inc. (NYSE:IFF). International Flavors & Fragrances Inc. (NYSE:IFF) is a specialty chemical company that manufactures products across food, beverage, health and biosciences, scent, pharma solutions, and complementary adjacent products. On July 14, 2026, International Flavors & Fragrances Inc. (NYSE:IFF) closed at $74.67 per share, reflecting a market capitalization of $19.06 billion. International Flavors & Fragrances Inc. (NYSE:IFF) posted a one-month return of -1.81%, while its shares gained 0.61% over the past 52 weeks.
Heartland Mid Cap Value Fund stated the following regarding International Flavors & Fragrances Inc. (NYSE:IFF) in its Q2 2026 investor update:
"Materials. A new deep-value holding is International Flavors & Fragrances Inc. (NYSE:IFF), a specialty ingredient producer that sells flavors, fragrances, and enzymes to food, beverage, personal care, household products, and human health product manufacturers. This is an example of identifying a self-help opportunity through bottom-up research.
For more than two years, management has worked on streamlining IFF's portfolio and operations to focus on higher-margin businesses where it enjoys leading market share, better pricing power, attractive growth, and significantly enhanced capital allocation flexibility. This strategy follows years of wayward capital allocation executed by prior management. Today, IFF's revenue is evenly split across three segments. Taste accounts for 30% of profits, Health & Biosciences generates 37%, and Scent contributes 32%. In the Scent segment, IFF's pioneering of encapsulated fragrance technology secured its leadership in fabric care, a position now expanding into scent boosters, shampoos, and body washes.
In its Q2 2026 investor letter, Heartland Mid Cap Value Fund highlighted International Flavors & Fragrances Inc. (NYSE:IFF). International Flavors & Fragrances Inc. (NYSE:IFF) is a specialty chemical company that manufactures products across food, beverage, health and biosciences, scent, pharma solutions, and complementary adjacent products. On July 14, 2026, International Flavors & Fragrances Inc. (NYSE:IFF) closed at $74.67 per share, reflecting a market capitalization of $19.06 billion. International Flavors & Fragrances Inc. (NYSE:IFF) posted a one-month return of -1.81%, while its shares gained 0.61% over the past 52 weeks.
Heartland Mid Cap Value Fund stated the following regarding International Flavors & Fragrances Inc. (NYSE:IFF) in its Q2 2026 investor update:
"Materials. A new deep-value holding is International Flavors & Fragrances Inc. (NYSE:IFF), a specialty ingredient producer that sells flavors, fragrances, and enzymes to food, beverage, personal care, household products, and human health product manufacturers. This is an example of identifying a self-help opportunity through bottom-up research.
For more than two years, management has worked on streamlining IFF's portfolio and operations to focus on higher-margin businesses where it enjoys leading market share, better pricing power, attractive growth, and significantly enhanced capital allocation flexibility. This strategy follows years of wayward capital allocation executed by prior management. Today, IFF's revenue is evenly split across three segments. Taste accounts for 30% of profits, Health & Biosciences generates 37%, and Scent contributes 32%. In the Scent segment, IFF's pioneering of encapsulated fragrance technology secured its leadership in fabric care, a position now expanding into scent boosters, shampoos, and body washes.
1 month ago
Cathie Wood has been taking it slow with her shopping sprees lately. The co-founder, CEO, and chief investment officer at Ark Invest has been doing more selling than buying across her firm's aggressive growth exchange-traded funds (ETFs).
Wood kicked off the new trading week by buying shares in ******* e Exploration (NASDAQ: SPCX), Roblox (NYSE: RBLX), and Alamar Biosciences (NASDAQ: ALMR). They were the only three stocks she purchased on Monday. Let's take a closer look at these fresh purchases.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
It's been a wild first six days of trading for ******* eX stock. Following the record-shattering IPO, shares rose sharply in their first three days on the market, only to give most of those gains away in the past three trading sessions.
Just 3% above its first-day trade of $150, the stock has shed nearly a third of its value since peaking a week ago. But despite the swift pullback, ******* eX remains one of just seven U.S. exchange-listed stocks with market caps north of $2 trillion.
Wood kicked off the new trading week by buying shares in ******* e Exploration (NASDAQ: SPCX), Roblox (NYSE: RBLX), and Alamar Biosciences (NASDAQ: ALMR). They were the only three stocks she purchased on Monday. Let's take a closer look at these fresh purchases.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
It's been a wild first six days of trading for ******* eX stock. Following the record-shattering IPO, shares rose sharply in their first three days on the market, only to give most of those gains away in the past three trading sessions.
Just 3% above its first-day trade of $150, the stock has shed nearly a third of its value since peaking a week ago. But despite the swift pullback, ******* eX remains one of just seven U.S. exchange-listed stocks with market caps north of $2 trillion.
1 month ago
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the 8 Best Genomics Stocks to Buy According to **** ysts.
On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized sub-$300 sequencing at scale. The company said the new chemistry cuts costs by about 30%. It also improved accuracy and yield through updates to its artificial intelligence-powered DeepConsensus algorithm developed with Google.
The company said beta testing across more than 1,400 runs showed higher yield and lower failure rates. **** ociate Professor and Senior Bioinformatician at Uppsala University, Adam Ameur, stated the system delivered "consistently strong run performance" with lower pricing and simplified workflows. CEO Christian Henry said AI advances, "improving data quality, speed, and usability," are expanding what researchers can extract from each run.
Product Lead for Genomics at Google Research, Andrew Carroll, added that DeepConsensus upgrades introduce more data quality, while PacBio said expanded methylation detection and reusable consumables increase output and reduce costs.
15 States with the Best Healthcare in the US
On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized sub-$300 sequencing at scale. The company said the new chemistry cuts costs by about 30%. It also improved accuracy and yield through updates to its artificial intelligence-powered DeepConsensus algorithm developed with Google.
The company said beta testing across more than 1,400 runs showed higher yield and lower failure rates. **** ociate Professor and Senior Bioinformatician at Uppsala University, Adam Ameur, stated the system delivered "consistently strong run performance" with lower pricing and simplified workflows. CEO Christian Henry said AI advances, "improving data quality, speed, and usability," are expanding what researchers can extract from each run.
Product Lead for Genomics at Google Research, Andrew Carroll, added that DeepConsensus upgrades introduce more data quality, while PacBio said expanded methylation detection and reusable consumables increase output and reduce costs.
15 States with the Best Healthcare in the US
2 months ago
Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.'s share was trading at $34.81 as of June 1st.
Likoper/Shutterstock.com
Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Its lead ****** et bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 ****** ets, expanding its optionality across solid tumors and hematologic malignancies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Likoper/Shutterstock.com
Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Its lead ****** et bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 ****** ets, expanding its optionality across solid tumors and hematologic malignancies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
8 months ago
In the fast-moving world of biotech innovation, few figures have commanded attention in 2025 the way Ben Lamm has.
As founder and CEO of Colossal Biosciences, he has transformed what sounded like science fiction into a high-stakes, headline-dominating movement.
His company’s mission, once dismissed as sensational, now sits at the center of global discussions about climate solutions, genetics, and the future of life itself.
Ben Lamm’s rise began with a concept that seemed almost too audacious to be real: bringing extinct species back into the modern world.
Colossal Biosciences quickly earne
As founder and CEO of Colossal Biosciences, he has transformed what sounded like science fiction into a high-stakes, headline-dominating movement.
His company’s mission, once dismissed as sensational, now sits at the center of global discussions about climate solutions, genetics, and the future of life itself.
Ben Lamm’s rise began with a concept that seemed almost too audacious to be real: bringing extinct species back into the modern world.
Colossal Biosciences quickly earne
